Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review (Q38075848)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2013

Language	Label	Description	Also known as
English	Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review	scientific article published on March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review (English)

1 reference

Europe PubMed Central

28 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

pharmacogenomics

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Martin Frank

1

1 reference

Europe PubMed Central

28 August 2017

Thomas Mittendorf

2

1 reference

Europe PubMed Central

28 August 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

28 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

28 August 2017

31

1 reference

Europe PubMed Central

28 August 2017

3

1 reference

Europe PubMed Central

28 August 2017

215-228

1 reference

Europe PubMed Central

28 August 2017

https://scigraph.springernature.com/pub.10.1007/s40273-012-0017-2

0 references

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Personalized medicine in oncology: the future is now.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Pharmacogenetics and pharmacogenomics: a clinical reality.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Personalized cancer medicine--advances and socio-economic challenges

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Actual 10-year survival after resection of colorectal liver metastases defines cure.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

A systematic review of treatment guidelines for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Pyrimidine degradation defects and severe 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

The role of pharmacogenetics in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Pharmacogenomics, evidence, and the role of payers

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

The future costs, risks and rewards of drug development: the economics of pharmacogenomics

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Impact of genetic diagnostics on drug development strategy.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

Clinical assessment incorporating a personal genome

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0017-2

21 January 2018

An update on the current and emerging targeted agents in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent progress and clinical importance on pharmacogenetics in cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current progress in targeted therapy for colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subgroups and heterogeneity in cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Personalized medicine in oncology: next generation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40273-012-0017-2

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38075848&oldid=2093613288"